Linagliptin/Metformin Stada

Linagliptin, the active ingredient in Linagliptin/Metformin Stada, is a DPP‑4 inhibitor presented as a tablet for oral use. Together with metformin hydrochloride, it forms a fixed‑dose combination that treats type 2 diabetes mellitus in adults by improving glycaemic control. It is indicated for patients who require additional glycaemic control beyond metformin alone.

GNH USA supplies Linagliptin/Metformin Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global markets and therapeutic.

Linagliptin/Metformin is used in the management of type 2 diabetes mellitus, a chronic metabolic disorder characterized by hyperglycaemia.

Type 2 diabetes mellitus: improves overall glycaemic control when added to diet and exercise, either as monotherapy or in combination with other antidiabetic agents. Inadequate control with metformin alone: provides additional reduction in HbA1c levels. Adjunct to other oral agents: enhances the efficacy of sulfonylureas, SGLT2 inhibitors or insulin when combined.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: loose stools, usually transient. - Abdominal discomfort: cramps or bloating. - Headache: mild tension‑type headache. - Dizziness: occasional light‑headedness. - Upper respiratory tract infection: mild cold‑like symptoms.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Hepatic failure: signs of liver dysfunction. - Allergic reactions: rash, pruritus, or angio‑edema. - Skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, evaluate patient-specific factors and monitor regularly. - Renal function: assess baseline eGFR and monitor periodically. - Hepatic function: evaluate liver enzymes in patients with known liver disease. - Lactic acidosis risk: avoid in patients with severe renal impairment or conditions predisposing to hypoxia. - Pregnancy and lactation: use only if potential benefit justifies the risk. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Linagliptin/Metformin may interact with several medicines; review concomitant therapy. Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated. - Concurrent use with other DPP‑4 inhibitors: risk of additive effects. - Co‑administration with iodinated contrast media in patients with reduced renal function: avoid. Moderate Interactions (Monitor Closely): - Metformin with cimetidine or trimethoprim: may increase metformin plasma levels; monitor renal function. - Linagliptin with strong CYP3A4 inhibitors (e.g., ketoconazole): may raise linagliptin exposure; consider dose adjustment.